9/18/2020  2:23:35 PM Chg. +0.270 Volume Bid2:24:00 PM Ask2:24:00 PM Market Capitalization Dividend Y. P/E Ratio
22.880EUR +1.19% 21,193
Turnover: 481,122.230
22.880Bid Size: 900 22.890Ask Size: 700 3.44 bill.EUR 0.00% 91.16

Business description

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease.
 

Management board & Supervisory board

CEO
Dr. Werner Lanthaler
Management board
Enno Spillner, Dr. Cord Dohrmann, Dr. Craig Johnstone
Supervisory board
Prof. Dr. Wolfgang Plischke, Prof. Dr. Iris Löw-Friedrich, Dr. Elaine Sullivan, Dr. Mario Polywka, Kasim Kutay, Roland Sackers
 

Company data

Name: Evotec SE
Address: Essener Bogen 7,D-22419 Hamburg
Phone: +49-40-56081-0
Fax: +49-40-56081-222
E-mail: info@evotec.com
Internet: www.evotec.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 61.59%
IPO date: 11/10/1999

Investor relations

Name: Gabriele Hansen
IR phone: +49-40-56081-255
IR Fax: +49-40-56081-333
IR e-mail: investorrelations@evotec.com

Company calendar

CW 46 | 11/12/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
61.59%
Novo A/S
 
10.10%
Roland Oetker / ROI Verwaltungsgesellschaft
 
9.16%
DWS Investment GmbH
 
5.02%
Allianz Global Investors Europe GmbH
 
4.89%
T. Rowe Price Group, Inc.
 
4.42%
BlackRock, Inc.
 
2.61%
The Goldman Sachs Group, Inc.
 
2.21%
Others
 
0.00%